Stocks Health care TAK

NYSE · Health care

Takeda Pharmaceutical Co Ltd (TAK)

Takeda Pharmaceutical Co Ltd reported revenue of ¥4.58T in fiscal 2025, up 7.5% from a year earlier. Net income was ¥107.9B, a net margin of 2.4%. Operating cash flow minus capital spending left ¥856.4B of free cash flow in fiscal 2025. At March 31, 2025 it held ¥385.1B in cash against ¥4.52T of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on June 17, 2026.

Watch TAK in 60 seconds

What Takeda Pharmaceutical Co Ltd does

Takeda Pharmaceutical Company researches, develops, and manufactures prescription medicines in therapeutic areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. It supplies pharmaceuticals to healthcare providers worldwide. Its shares trade on NYSE under the ticker TAK.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in JPY.

Key figures

Full financial statements: income, balance sheet and cash flow

Where TAK ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Dividends

It paid out ¥302.5B in cash dividends, 280% of its net income.

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Takeda Pharmaceutical Co Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 14, 2026
   Foreign issuer update 6-K
2. August 31, 2026
   Foreign issuer update 6-K
3. August 6, 2026
   Foreign issuer update 6-K
4. July 30, 2026
   Foreign issuer update 6-K
5. July 9, 2026
   Foreign issuer update 6-K
6. July 8, 2026
   Foreign issuer update 6-K
7. June 29, 2026
   Foreign issuer update 6-K
8. June 26, 2026
   Foreign issuer update 6-K
9. June 24, 2026
   Foreign issuer update 6-K
10. June 24, 2026
    Foreign issuer update 6-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 15, 2026. Insider transactions on SEC

Insider trades

What the people running Takeda Pharmaceutical Co Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $13.1M worth of shares in the last 90 days and bought none on the open market. 19% of the selling was pre-planned under Rule 10b5-1 trading plans.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TAK

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

25 insiders reported holding 4,737,961 shares in total, about $89.5M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TAK

What does Takeda Pharmaceutical Co Ltd do?

Takeda Pharmaceutical Company researches, develops, and manufactures prescription medicines in therapeutic areas such as oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. It supplies pharmaceuticals to healthcare providers worldwide. Its shares trade on NYSE under the ticker TAK.

Is Takeda Pharmaceutical Co Ltd profitable?

Yes. In fiscal 2025 it reported net income of ¥107.9B on revenue of ¥4.58T, a net margin of 2.4%.

How much revenue does Takeda Pharmaceutical Co Ltd make?

In fiscal 2025 Takeda Pharmaceutical Co Ltd reported revenue of ¥4.58T. That is 7.5% more than a year earlier.

When did Takeda Pharmaceutical Co Ltd last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on June 17, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the insider trade from September 15, 2026.

Similar companies

Compare TAK with

Compare TAK with any company

Follow TAK

Get an email when Takeda Pharmaceutical Co Ltd files with the SEC: results, executive changes, material agreements and annual reports.

Follow TAK: get an email when it files

Where the numbers come from

Financial figures are the values Takeda Pharmaceutical Co Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.